



**PHARMACY AND THERAPEUTICS COMMITTEE  
ACA/Exchange MEETING MINUTES  
May 13, 2025**

*Attendance:* Microsoft Teams Meeting  
Yumna Ahmed, Pharmacy Student Intern; Dr. Paul Aitken, Medical Director; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovec, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Jessica Tran, Staff/Clinical Pharmacist; Fallon Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist

*Excused:* Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Dr. Demian Elder, Medical Director; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health

*Minutes taken by:* Joana Iverson

**I. Administrative Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
<b><i>Minutes Review/Approval</i></b>	<i>D. Dolores presented the minutes from the March 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>

## II. Prior Authorization Review/Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
<b>2026 Formulary Additions</b>	<p><i>The Committee reviewed the Formulary Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <li>• <i>Advate - T5, PA</i></li> <li>• <i>Adynovate - T5, PA</i></li> <li>• <i>Afstyla - T5, PA</i></li> <li>• <i>Alphanate - T5, PA</i></li> <li>• <i>AlphaNine SD - T5, PA</i></li> <li>• <i>Alprolix - T5, PA</i></li> <li>• <i>Altuviiiio - T5, PA</i></li> <li>• <i>BeneFIX - T5, PA</i></li> <li>• <i>Brimonidine tartrate 0.1% solution - T2</i></li> <li>• <i>Eloctate - T5, PA</i></li> <li>• <i>Feiba - T5, PA</i></li> <li>• <i>Hemlibra - T5, PA</i></li> <li>• <i>Hemofil M - T5, PA</i></li> <li>• <i>Humate-P - T5, PA</i></li> <li>• <i>Ixinity - T5, PA</i></li> <li>• <i>Jivi - T5, PA</i></li> <li>• <i>Koate - T5, PA</i></li> <li>• <i>Koate-DVI - T5, PA</i></li> <li>• <i>Kogenate FS - T5, PA</i></li> <li>• <i>Kovaltry - T5, PA</i></li> <li>• <i>Lantus - T3</i></li> <li>• <i>Lantus SoloStar - T3</i></li> <li>• <i>Mononine - T5, PA</i></li> <li>• <i>Novoeight - T5, PA</i></li> <li>• <i>NovoSeven RT - T5, PA</i></li> <li>• <i>Nuwiq - T5, PA</i></li> <li>• <i>Profilnine - T5, PA</i></li> <li>• <i>Qulipta - T3, QL 30/30 days, PA</i></li> <li>• <i>Rebinyn - T5, PA</i></li> <li>• <i>Recombinate - T5, PA</i></li> <li>• <i>Rixubis - T5, PA</i></li> <li>• <i>Sevenfact - T5, PA</i></li> <li>• <i>Tazarotene 0.05% cream - T2, PA</i></li> <li>• <i>Velsipity - T5, PA</i></li> <li>• <i>Wilate - T5, PA</i></li> <li>• <i>Xyntha - T5, PA</i></li> <li>• <i>Xyntha Solofuse - T5, PA</i></li> </ul>	<i>The Committee approved as presented.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
<b>2026 Formulary Removals</b>	<p><i>The Committee reviewed the Formulary Removals.</i></p> <ul style="list-style-type: none"> <li>• <i>Alphagan P (generic covered)</i></li> <li>• <i>APO-varenicline</i></li> <li>• <i>Avonex Pen</i></li> <li>• <i>Avonex Prefilled Syringe</i></li> <li>• <i>Basaglar KwikPen</i></li> <li>• <i>Fuzeon</i></li> <li>• <i>Gomekli</i></li> <li>• <i>Hetlioz LQ</i></li> <li>• <i>Iclusig</i></li> <li>• <i>Invega Hafyera</i></li> <li>• <i>Invega Trinza</i></li> <li>• <i>Ketoprofen</i></li> <li>• <i>Ketoprofen ER</i></li> <li>• <i>Levemir</i></li> <li>• <i>Levemir FlexTouch</i></li> <li>• <i>Lexiva suspension</i></li> <li>• <i>Lucemyra (generic covered)</i></li> <li>• <i>Methamphetamine 5 mg tablet</i></li> <li>• <i>Myrbetriq (generic covered)</i></li> <li>• <i>Natpara</i></li> <li>• <i>Nitrolingual</i></li> <li>• <i>Nucala</i></li> <li>• <i>Plegridy</i></li> <li>• <i>Ridaura (generic covered)</i></li> <li>• <i>Simponi</i></li> <li>• <i>Simponi Aria</i></li> <li>• <i>Sprycel (generic covered)</i></li> <li>• <i>Trientine 500 mg capsule</i></li> <li>• <i>Verzenio</i></li> <li>• <i>Viracept</i></li> <li>• <i>Xyrem (generic covered)</i></li> <li>• <i>Yonsa</i></li> </ul>	<i>The Committee approved as presented.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>
<b>2026 Tier Changes</b>	<p><i>The Committee reviewed the Tier Changes. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <li>• <i>Cabenuva - Move to T4</i></li> <li>• <i>Clovisque/trientine - Move to T2</i></li> <li>• <i>Descovy - Move to T0</i></li> <li>• <i>Emtricitabine-Tenofovir DF - Move to T0</i></li> <li>• <i>Mesna - Move to T2</i></li> </ul>	<i>The Committee approved as presented.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>• Paxlovid - Move to T2</li> <li>• Repatha Pushtronex System - Move to T3</li> <li>• Sublocade - Move to T3</li> <li>• Symtuza - Move to T3</li> <li>• Triumeq/Triumeq PD - Move to T4</li> </ul>			


### III. Drug Formulary Review/Update

<b>2025 Prior Authorization Review</b>	<p>The Committee reviewed the Prior Authorization updates and approved as presented.</p> <ul style="list-style-type: none"> <li>• Xdemvy</li> <li>• Strensiq</li> </ul>	The Committee reviewed the Prior Authorization updates and approved as presented.	J. Crawford F. Vaisberg	Resolved
<b>2025 Formulary Additions</b>	<p>The Committee reviewed the 2025 Formulary Additions and approved as presented.</p> <ul style="list-style-type: none"> <li>• Adalimumab-adaz 10 mg/0.1mL soln prsyr - T5, PA</li> <li>• Amnesteem 30 mg cap - T2, PA</li> <li>• Auranofin 3 mg cap - T4</li> <li>• Feirza 1/20 1-20 mg-mcg tab - T0</li> <li>• Ft naloxone hcl 4 mg/0.1mL liquid - T1</li> <li>• Gomekli 1 mg cap - T5, PA</li> <li>• Gomekli 1 mg tab sol - T5, PA</li> <li>• Gomekli 2 mg cap - T5, PA</li> <li>• Kaletra 400-100 mg/5mL solution - T3, QL 480/30</li> <li>• Multivitamin/fluoride 0.25 mg/mL solution - T2</li> <li>• Ondansetron hcl +rfd 4 mg/2mL solution - T2</li> <li>• Paxlovid 6 x 150 mg &amp; 5 x 100mg tab thpk - T3, QL 30/30</li> <li>• Pitavastatin calcium 1 mg tablet - T0, 30/30 days</li> <li>• Pitavastatin calcium 2 mg tablet - T0, 30/30 days</li> <li>• Pitavastatin calcium 4 mg tablet - T0, 30/30 days</li> <li>• Retaine allergy 0.2 % solution - T2</li> <li>• Revuforj 110 mg tab - T5, PA</li> <li>• Revuforj 160 mg tab - T5, PA</li> <li>• Revuforj 25 mg tab - T5, PA</li> <li>• Tremfya crohns induction 200 mg/2mL soln a-inj - T5, PA</li> <li>• Tremfya pen 100 mg/ml soln a-inj - T5, PA</li> <li>• Xarah fe 1-20/1-30/1-35 mg-mcg tab - T0</li> <li>• Xelria fe 0.4-35 mg-mcg chew tab - T0</li> <li>• Xpovio (40 mg once weekly) 10 mg tab thpk - T5, PA</li> </ul>	The Committee reviewed the 2025 Formulary Additions and approved as presented.	F. Vaisberg	Resolved

<b>IV. New Drug Review</b>	<i>(Presented in New Drug Review for Medicaid.) The following new products were reviewed and will be kept as non-formulary: *Refer to May 2025 Medicare Minutes</i>	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>R. John</i>	<i>Resolved</i>
----------------------------	---	---	----------------	-----------------

**V. Adjournment**

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held August 2025.



5/22/2025

\_\_\_\_\_  
Danielle Dolores, Director of Pharmacy Services

\_\_\_\_\_  
Date